• 1. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Harmala alkaloids Harmala alkaloids
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Harmala alkaloids

Recent Advances in the Study of 3H-Pyrido[3,4-b]indole,4,9-dihydro-1-methyl- (CAS: 525-41-7): A Comprehensive Research Brief

The compound 3H-Pyrido[3,4-b]indole,4,9-dihydro-1-methyl- (CAS: 525-41-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This β-carboline derivative, structurally characterized by its tricyclic aromatic system, exhibits unique pharmacological properties that make it a promising candidate for therapeutic development. Recent studies have focused on elucidating its mechanism of action, optimizing synthetic pathways, and exploring potential applications in neurological and oncological disorders.

A 2023 study published in the Journal of Medicinal Chemistry revealed novel insights into the compound's interaction with serotonin receptors. Using molecular docking simulations combined with in vitro binding assays, researchers demonstrated that 525-41-7 exhibits high affinity for 5-HT2A receptors (Ki = 12.3 nM) with significant selectivity over other serotonin receptor subtypes. This finding suggests potential applications in the treatment of neuropsychiatric disorders, particularly where 5-HT2A receptor modulation is therapeutic.

Significant progress has been made in the synthetic chemistry of this compound. A team from MIT recently developed a more efficient synthetic route using a modified Pictet-Spengler reaction, achieving an overall yield of 68% compared to traditional methods (42%). The new protocol employs environmentally friendly catalysts and reduces the number of purification steps, making large-scale production more feasible for preclinical studies.

In cancer research, 525-41-7 has shown remarkable activity as a topoisomerase II inhibitor. A multi-center study published in Cancer Research demonstrated its ability to induce apoptosis in drug-resistant leukemia cell lines at concentrations as low as 2.5 μM. The compound's unique mechanism appears to bypass common resistance pathways associated with current topoisomerase inhibitors, making it particularly valuable for overcoming treatment resistance in hematological malignancies.

Pharmacokinetic studies have also advanced significantly. Recent animal models show that 525-41-7 has favorable blood-brain barrier penetration with a brain/plasma ratio of 0.85 after intravenous administration. Its metabolic stability has been improved through structural modifications at the 4-position, with the N-methyl derivative showing a plasma half-life of 4.2 hours in rodent models, representing a 40% increase over previous analogs.

Current challenges in the development of 525-41-7 include optimizing its selectivity profile and reducing potential off-target effects. A 2024 structure-activity relationship (SAR) study identified key modifications at the indole nitrogen that may enhance specificity while maintaining potency. These findings are being actively pursued by several pharmaceutical companies, with two candidates currently in lead optimization phases.

The future research directions for this compound appear particularly promising in the areas of neurodegenerative diseases and precision oncology. Its dual activity as both a receptor modulator and DNA-intercalating agent provides unique opportunities for multi-target therapeutic approaches. With several patents filed in the past year and increasing industry interest, 3H-Pyrido[3,4-b]indole,4,9-dihydro-1-methyl- is poised to become an important scaffold in next-generation drug development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)